Energy metabolism as a target for cyclobenzaprine: A drug candidate against Visceral Leishmaniasis

[Display omitted] •Cyclobenzaprine caused a decrease of ATP in L. infantum promastigotes.•The drug induced an irreversible depolarization of plasma membrane.•The drug collapsed the mitochondrial electrochemical potential.•It also induced Ca2+ imbalance and DNA fragmentation.•Cyclobenzaprine can be c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bioorganic chemistry 2022-10, Vol.127, p.106009-106009, Article 106009
Hauptverfasser: Lima, Marta Lopes, Abengózar, Maria A., Torres-Santos, Eduardo Caio, Borborema, Samanta Etel Treiger, Godzien, Joanna, López-Gonzálvez, Ángeles, Barbas, Coral, Rivas, Luis, Tempone, Andre Gustavo
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 106009
container_issue
container_start_page 106009
container_title Bioorganic chemistry
container_volume 127
creator Lima, Marta Lopes
Abengózar, Maria A.
Torres-Santos, Eduardo Caio
Borborema, Samanta Etel Treiger
Godzien, Joanna
López-Gonzálvez, Ángeles
Barbas, Coral
Rivas, Luis
Tempone, Andre Gustavo
description [Display omitted] •Cyclobenzaprine caused a decrease of ATP in L. infantum promastigotes.•The drug induced an irreversible depolarization of plasma membrane.•The drug collapsed the mitochondrial electrochemical potential.•It also induced Ca2+ imbalance and DNA fragmentation.•Cyclobenzaprine can be considered a promising drug candidate. Leishmaniases have a broad spectrum of clinical manifestations, ranging from a cutaneous to a progressive and fatal visceral disease. Chemotherapy is nowadays the almost exclusive way to fight the disease but limited by its scarce therapeutic arsenal, on its own compromised by adverse side effects and clinical resistance. Cyclobenzaprine (CBP), an FDA-approved oral muscle relaxant drug has previously demonstrated in vitro and in vivo activity against Leishmania sp., but its targets were not fully unveiled. This study aimed to define the role of energy metabolism as a target for the leishmanicidal mechanisms of CBP. Methodology to assess CBP leishmanicidal mechanism variation of intracellular ATP levels using living Leishmania transfected with a cytoplasmic luciferase. Induction of plasma membrane permeability by assessing depolarization with DiSBAC(2)3 and entrance of the vital dye SYTOX® Green. Mitochondrial depolarization by rhodamine 123 accumulation. Mapping target site within the respiratory chain by oxygen consumption rate. Reactive oxygen species (ROS) production using MitoSOX. Morphological changes by transmission electron microscopy. CBP caused on L. infantum promastigotes a decrease of intracellular ATP levels, with irreversible depolarization of plasma membrane, the collapse of the mitochondrial electrochemical potential, mild uncoupling of the respiratory chain, and ROS production, with ensuing intracellular Ca2+ imbalance and DNA fragmentation. Electron microscopy supported autophagic features but not a massive plasma membrane disruption. The severe and irreversible mitochondrial damage induced by CBP endorsed the bioenergetics metabolism as a relevant target within the lethal programme induced by CBP in Leishmania. This, together with the mild-side effects of this oral drug, endorses CBP as an appealing novel candidate as a leishmanicidal drug under a drug repurposing strategy.
doi_str_mv 10.1016/j.bioorg.2022.106009
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2691050679</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0045206822004151</els_id><sourcerecordid>2691050679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c269t-2e576de174741f94ca000655afbc0daace0b311515676fb9ebd9e668ca36b5053</originalsourceid><addsrcrecordid>eNp9kE9LxDAQxYMouK5-Aw85euk66Tap9SAsi_9gwYt6DZN0WrO0jSZZYf30dqlnTwPDe2_m_Ri7FLAQINT1dmGc96Fd5JDn40oBVEdsJqCCLBc5HLMZQCGzHNTNKTuLcQsgRFGqGTP3A4V2z3tKaHznYs8xcuQJQ0uJNz5wu7edNzT84GdwA93yFa_DruUWh9rVmIhji26Iib-7aClgxzfk4kePg8Po4jk7abCLdPE35-zt4f51_ZRtXh6f16tNZnNVpSwnWaqaRFmUhWiqwiIAKCmxMRZqREtglkJIIVWpGlORqStS6sbiUhkJcjlnV1PuZ_BfO4pJ94d_ug4H8ruoxysCJKiyGqXFJLXBxxio0WO1HsNeC9AHpHqrJ6T6gFRPSEfb3WSjsca3o6CjdTRYql0gm3Tt3f8Bv_FbgiM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2691050679</pqid></control><display><type>article</type><title>Energy metabolism as a target for cyclobenzaprine: A drug candidate against Visceral Leishmaniasis</title><source>Elsevier ScienceDirect Journals Complete</source><creator>Lima, Marta Lopes ; Abengózar, Maria A. ; Torres-Santos, Eduardo Caio ; Borborema, Samanta Etel Treiger ; Godzien, Joanna ; López-Gonzálvez, Ángeles ; Barbas, Coral ; Rivas, Luis ; Tempone, Andre Gustavo</creator><creatorcontrib>Lima, Marta Lopes ; Abengózar, Maria A. ; Torres-Santos, Eduardo Caio ; Borborema, Samanta Etel Treiger ; Godzien, Joanna ; López-Gonzálvez, Ángeles ; Barbas, Coral ; Rivas, Luis ; Tempone, Andre Gustavo</creatorcontrib><description>[Display omitted] •Cyclobenzaprine caused a decrease of ATP in L. infantum promastigotes.•The drug induced an irreversible depolarization of plasma membrane.•The drug collapsed the mitochondrial electrochemical potential.•It also induced Ca2+ imbalance and DNA fragmentation.•Cyclobenzaprine can be considered a promising drug candidate. Leishmaniases have a broad spectrum of clinical manifestations, ranging from a cutaneous to a progressive and fatal visceral disease. Chemotherapy is nowadays the almost exclusive way to fight the disease but limited by its scarce therapeutic arsenal, on its own compromised by adverse side effects and clinical resistance. Cyclobenzaprine (CBP), an FDA-approved oral muscle relaxant drug has previously demonstrated in vitro and in vivo activity against Leishmania sp., but its targets were not fully unveiled. This study aimed to define the role of energy metabolism as a target for the leishmanicidal mechanisms of CBP. Methodology to assess CBP leishmanicidal mechanism variation of intracellular ATP levels using living Leishmania transfected with a cytoplasmic luciferase. Induction of plasma membrane permeability by assessing depolarization with DiSBAC(2)3 and entrance of the vital dye SYTOX® Green. Mitochondrial depolarization by rhodamine 123 accumulation. Mapping target site within the respiratory chain by oxygen consumption rate. Reactive oxygen species (ROS) production using MitoSOX. Morphological changes by transmission electron microscopy. CBP caused on L. infantum promastigotes a decrease of intracellular ATP levels, with irreversible depolarization of plasma membrane, the collapse of the mitochondrial electrochemical potential, mild uncoupling of the respiratory chain, and ROS production, with ensuing intracellular Ca2+ imbalance and DNA fragmentation. Electron microscopy supported autophagic features but not a massive plasma membrane disruption. The severe and irreversible mitochondrial damage induced by CBP endorsed the bioenergetics metabolism as a relevant target within the lethal programme induced by CBP in Leishmania. This, together with the mild-side effects of this oral drug, endorses CBP as an appealing novel candidate as a leishmanicidal drug under a drug repurposing strategy.</description><identifier>ISSN: 0045-2068</identifier><identifier>EISSN: 1090-2120</identifier><identifier>DOI: 10.1016/j.bioorg.2022.106009</identifier><language>eng</language><publisher>Elsevier Inc</publisher><subject>Cyclobenzaprine ; Drug repurposing ; Leishmania ; Leishmaniasis ; Mechanism of action ; Neglected diseases</subject><ispartof>Bioorganic chemistry, 2022-10, Vol.127, p.106009-106009, Article 106009</ispartof><rights>2022 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c269t-2e576de174741f94ca000655afbc0daace0b311515676fb9ebd9e668ca36b5053</citedby><cites>FETCH-LOGICAL-c269t-2e576de174741f94ca000655afbc0daace0b311515676fb9ebd9e668ca36b5053</cites><orcidid>0000-0003-4722-491X ; 0000-0002-6363-7135</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.bioorg.2022.106009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids></links><search><creatorcontrib>Lima, Marta Lopes</creatorcontrib><creatorcontrib>Abengózar, Maria A.</creatorcontrib><creatorcontrib>Torres-Santos, Eduardo Caio</creatorcontrib><creatorcontrib>Borborema, Samanta Etel Treiger</creatorcontrib><creatorcontrib>Godzien, Joanna</creatorcontrib><creatorcontrib>López-Gonzálvez, Ángeles</creatorcontrib><creatorcontrib>Barbas, Coral</creatorcontrib><creatorcontrib>Rivas, Luis</creatorcontrib><creatorcontrib>Tempone, Andre Gustavo</creatorcontrib><title>Energy metabolism as a target for cyclobenzaprine: A drug candidate against Visceral Leishmaniasis</title><title>Bioorganic chemistry</title><description>[Display omitted] •Cyclobenzaprine caused a decrease of ATP in L. infantum promastigotes.•The drug induced an irreversible depolarization of plasma membrane.•The drug collapsed the mitochondrial electrochemical potential.•It also induced Ca2+ imbalance and DNA fragmentation.•Cyclobenzaprine can be considered a promising drug candidate. Leishmaniases have a broad spectrum of clinical manifestations, ranging from a cutaneous to a progressive and fatal visceral disease. Chemotherapy is nowadays the almost exclusive way to fight the disease but limited by its scarce therapeutic arsenal, on its own compromised by adverse side effects and clinical resistance. Cyclobenzaprine (CBP), an FDA-approved oral muscle relaxant drug has previously demonstrated in vitro and in vivo activity against Leishmania sp., but its targets were not fully unveiled. This study aimed to define the role of energy metabolism as a target for the leishmanicidal mechanisms of CBP. Methodology to assess CBP leishmanicidal mechanism variation of intracellular ATP levels using living Leishmania transfected with a cytoplasmic luciferase. Induction of plasma membrane permeability by assessing depolarization with DiSBAC(2)3 and entrance of the vital dye SYTOX® Green. Mitochondrial depolarization by rhodamine 123 accumulation. Mapping target site within the respiratory chain by oxygen consumption rate. Reactive oxygen species (ROS) production using MitoSOX. Morphological changes by transmission electron microscopy. CBP caused on L. infantum promastigotes a decrease of intracellular ATP levels, with irreversible depolarization of plasma membrane, the collapse of the mitochondrial electrochemical potential, mild uncoupling of the respiratory chain, and ROS production, with ensuing intracellular Ca2+ imbalance and DNA fragmentation. Electron microscopy supported autophagic features but not a massive plasma membrane disruption. The severe and irreversible mitochondrial damage induced by CBP endorsed the bioenergetics metabolism as a relevant target within the lethal programme induced by CBP in Leishmania. This, together with the mild-side effects of this oral drug, endorses CBP as an appealing novel candidate as a leishmanicidal drug under a drug repurposing strategy.</description><subject>Cyclobenzaprine</subject><subject>Drug repurposing</subject><subject>Leishmania</subject><subject>Leishmaniasis</subject><subject>Mechanism of action</subject><subject>Neglected diseases</subject><issn>0045-2068</issn><issn>1090-2120</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kE9LxDAQxYMouK5-Aw85euk66Tap9SAsi_9gwYt6DZN0WrO0jSZZYf30dqlnTwPDe2_m_Ri7FLAQINT1dmGc96Fd5JDn40oBVEdsJqCCLBc5HLMZQCGzHNTNKTuLcQsgRFGqGTP3A4V2z3tKaHznYs8xcuQJQ0uJNz5wu7edNzT84GdwA93yFa_DruUWh9rVmIhji26Iib-7aClgxzfk4kePg8Po4jk7abCLdPE35-zt4f51_ZRtXh6f16tNZnNVpSwnWaqaRFmUhWiqwiIAKCmxMRZqREtglkJIIVWpGlORqStS6sbiUhkJcjlnV1PuZ_BfO4pJ94d_ug4H8ruoxysCJKiyGqXFJLXBxxio0WO1HsNeC9AHpHqrJ6T6gFRPSEfb3WSjsca3o6CjdTRYql0gm3Tt3f8Bv_FbgiM</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Lima, Marta Lopes</creator><creator>Abengózar, Maria A.</creator><creator>Torres-Santos, Eduardo Caio</creator><creator>Borborema, Samanta Etel Treiger</creator><creator>Godzien, Joanna</creator><creator>López-Gonzálvez, Ángeles</creator><creator>Barbas, Coral</creator><creator>Rivas, Luis</creator><creator>Tempone, Andre Gustavo</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4722-491X</orcidid><orcidid>https://orcid.org/0000-0002-6363-7135</orcidid></search><sort><creationdate>202210</creationdate><title>Energy metabolism as a target for cyclobenzaprine: A drug candidate against Visceral Leishmaniasis</title><author>Lima, Marta Lopes ; Abengózar, Maria A. ; Torres-Santos, Eduardo Caio ; Borborema, Samanta Etel Treiger ; Godzien, Joanna ; López-Gonzálvez, Ángeles ; Barbas, Coral ; Rivas, Luis ; Tempone, Andre Gustavo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c269t-2e576de174741f94ca000655afbc0daace0b311515676fb9ebd9e668ca36b5053</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cyclobenzaprine</topic><topic>Drug repurposing</topic><topic>Leishmania</topic><topic>Leishmaniasis</topic><topic>Mechanism of action</topic><topic>Neglected diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lima, Marta Lopes</creatorcontrib><creatorcontrib>Abengózar, Maria A.</creatorcontrib><creatorcontrib>Torres-Santos, Eduardo Caio</creatorcontrib><creatorcontrib>Borborema, Samanta Etel Treiger</creatorcontrib><creatorcontrib>Godzien, Joanna</creatorcontrib><creatorcontrib>López-Gonzálvez, Ángeles</creatorcontrib><creatorcontrib>Barbas, Coral</creatorcontrib><creatorcontrib>Rivas, Luis</creatorcontrib><creatorcontrib>Tempone, Andre Gustavo</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bioorganic chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lima, Marta Lopes</au><au>Abengózar, Maria A.</au><au>Torres-Santos, Eduardo Caio</au><au>Borborema, Samanta Etel Treiger</au><au>Godzien, Joanna</au><au>López-Gonzálvez, Ángeles</au><au>Barbas, Coral</au><au>Rivas, Luis</au><au>Tempone, Andre Gustavo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Energy metabolism as a target for cyclobenzaprine: A drug candidate against Visceral Leishmaniasis</atitle><jtitle>Bioorganic chemistry</jtitle><date>2022-10</date><risdate>2022</risdate><volume>127</volume><spage>106009</spage><epage>106009</epage><pages>106009-106009</pages><artnum>106009</artnum><issn>0045-2068</issn><eissn>1090-2120</eissn><abstract>[Display omitted] •Cyclobenzaprine caused a decrease of ATP in L. infantum promastigotes.•The drug induced an irreversible depolarization of plasma membrane.•The drug collapsed the mitochondrial electrochemical potential.•It also induced Ca2+ imbalance and DNA fragmentation.•Cyclobenzaprine can be considered a promising drug candidate. Leishmaniases have a broad spectrum of clinical manifestations, ranging from a cutaneous to a progressive and fatal visceral disease. Chemotherapy is nowadays the almost exclusive way to fight the disease but limited by its scarce therapeutic arsenal, on its own compromised by adverse side effects and clinical resistance. Cyclobenzaprine (CBP), an FDA-approved oral muscle relaxant drug has previously demonstrated in vitro and in vivo activity against Leishmania sp., but its targets were not fully unveiled. This study aimed to define the role of energy metabolism as a target for the leishmanicidal mechanisms of CBP. Methodology to assess CBP leishmanicidal mechanism variation of intracellular ATP levels using living Leishmania transfected with a cytoplasmic luciferase. Induction of plasma membrane permeability by assessing depolarization with DiSBAC(2)3 and entrance of the vital dye SYTOX® Green. Mitochondrial depolarization by rhodamine 123 accumulation. Mapping target site within the respiratory chain by oxygen consumption rate. Reactive oxygen species (ROS) production using MitoSOX. Morphological changes by transmission electron microscopy. CBP caused on L. infantum promastigotes a decrease of intracellular ATP levels, with irreversible depolarization of plasma membrane, the collapse of the mitochondrial electrochemical potential, mild uncoupling of the respiratory chain, and ROS production, with ensuing intracellular Ca2+ imbalance and DNA fragmentation. Electron microscopy supported autophagic features but not a massive plasma membrane disruption. The severe and irreversible mitochondrial damage induced by CBP endorsed the bioenergetics metabolism as a relevant target within the lethal programme induced by CBP in Leishmania. This, together with the mild-side effects of this oral drug, endorses CBP as an appealing novel candidate as a leishmanicidal drug under a drug repurposing strategy.</abstract><pub>Elsevier Inc</pub><doi>10.1016/j.bioorg.2022.106009</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-4722-491X</orcidid><orcidid>https://orcid.org/0000-0002-6363-7135</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0045-2068
ispartof Bioorganic chemistry, 2022-10, Vol.127, p.106009-106009, Article 106009
issn 0045-2068
1090-2120
language eng
recordid cdi_proquest_miscellaneous_2691050679
source Elsevier ScienceDirect Journals Complete
subjects Cyclobenzaprine
Drug repurposing
Leishmania
Leishmaniasis
Mechanism of action
Neglected diseases
title Energy metabolism as a target for cyclobenzaprine: A drug candidate against Visceral Leishmaniasis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T11%3A07%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Energy%20metabolism%20as%20a%20target%20for%20cyclobenzaprine:%20A%20drug%20candidate%20against%20Visceral%20Leishmaniasis&rft.jtitle=Bioorganic%20chemistry&rft.au=Lima,%20Marta%20Lopes&rft.date=2022-10&rft.volume=127&rft.spage=106009&rft.epage=106009&rft.pages=106009-106009&rft.artnum=106009&rft.issn=0045-2068&rft.eissn=1090-2120&rft_id=info:doi/10.1016/j.bioorg.2022.106009&rft_dat=%3Cproquest_cross%3E2691050679%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2691050679&rft_id=info:pmid/&rft_els_id=S0045206822004151&rfr_iscdi=true